In the latest example of how the high price tags for hepatitis C drugs are limiting use in some of the most infected populations, two inmates in Massachusetts state prisons have filed a lawsuit accusing the state prison system of failing to provide the drugs to most infected prisoners.
More than 1,500 inmates in Massachusetts state prisons have hepatitis C, but only three are being treated for it, the lawsuit states, even though Gilead Sciences GILD +1.23% and AbbVie ABBV -0.29% introduced drugs since late 2013 that have higher cure rates and shorter treatment durations than older hepatitis C regimens.
Hey, check out all the research scientist jobs. Post your resume today!
